TELO

Telomir Pharmaceuticals, Inc. Common Stock (TELO) Economic Moat Analysis (2026)

Invetso Score: 1.1/10 — Weak · Last Updated: 2026-09-01

Monthly Update

No material changes this month.

Intangible Assets

Score: 1.2 (Weak)

TELO does not show evidence of durable brand, patent, or regulatory-intangible advantages in the provided filings-based metrics, so it lacks the pricing power seen in stronger peer moats.

Negative TTM ROIC and ROCE indicate the company is not yet converting any intangible position into superior returns, unlike peers with established proprietary assets.

With no disclosed long-run margin or growth history in the supplied data, there is no sign of a persistent customer preference advantage versus better-positioned competitors.

Switching Costs

Score:

The provided data does not indicate contractual lock-in, embedded workflows, or integration depth, so customers appear able to switch without material friction.

Negative capital returns suggest TELO has not built a sticky installed base that would support retention better than peers.

Compared with software- or infrastructure-like peers that benefit from high renewal dependence, TELO shows no visible evidence of switching-cost protection.

Network Effects

Score:

No evidence in the supplied metrics suggests user-to-user, data, or ecosystem feedback loops that would strengthen TELO’s position as adoption scales.

Negative ROIC and zero asset turnover do not support a self-reinforcing platform dynamic, unlike peers with compounding network benefits.

Absent disclosed ecosystem control or peer dependency, network effects appear immaterial to TELO’s durability.

Cost Advantage

Score:

Negative TTM ROIC and ROCE imply TELO is not operating with a cost structure that converts into superior unit economics versus peers.

The supplied efficiency metrics show zero asset turnover and zero cash conversion cycle, which does not evidence a scalable cost edge over competitors.

Without demonstrated margin resilience or operating leverage, TELO does not appear to have a durable cost advantage.

Efficient Scale

Score:

The available data does not show a protected niche or capacity-constrained market structure that would let TELO earn excess returns without inviting peer retaliation.

Negative returns on capital indicate scale is not yet translating into defensible economics, unlike incumbents in concentrated markets.

There is no evidence of industry dependency or local monopoly-like conditions that would support efficient-scale protection.

Overall Score

Score:

TELO currently shows no visible structural moat in the supplied filings-based metrics, and its negative capital returns versus stronger peers suggest limited pricing power, weak retention, and no durable advantage across the five moat drivers.

Sources

  • Company filings (10-K, 10-Q, investor presentations)
  • Financial and market data providers
  • Public news and industry information

🔒 Go Beyond This Framework

This is one of 10 institutional-grade frameworks Invetso runs on Telomir Pharmaceuticals, Inc. Common Stock. Unlock the complete analysis — SWOT, Economic Moat, Porter’s Five Forces, Management, PESTLE and the Invetso Quality Score.

Create your free account on Invetso →